19 November 2009 - Actelion Ltd announced today that a supplemental new drug application (sNDA) for an extension of indication for Zavesca® (miglustat) for the treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick type C disease (NP-C) has been accepted by the U.S. Food and Drug Administration (FDA).
The details can be read here.
No comments:
Post a Comment